Ahmed Sawas, MD
Hematology · New York, NYNPI 1134379043
Payments from drug & device makers
Across 673 payments — averaging $1401.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$283K
- Seagen Inc.$168K
- Daiichi Sankyo Inc.$145K
- Gilead$100K
- Lilly USA, LLC$85K
- Pfizer$47K
- plus $116K from 23 others
Across 1 payment — averaging $270.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$271
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 4 | $283,093 |
| Seagen Inc. | 144 | $168,454 |
| Daiichi Sankyo Inc. | 155 | $144,723 |
| Gilead(2 entities) | 82 | $99,574 |
| Lilly USA, LLC | 73 | $84,786 |
| Pfizer | 40 | $46,606 |
| Acrotech Biopharma Inc. | 44 | $38,570 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32,313 |
| Kyowa Kirin, Inc. | 22 | $16,275 |
| Aurobindo Pharma USA, Inc. | 39 | $14,060 |
| Pharmacyclics LLC, An Abbvie Company | 27 | $6,518 |
| Pharmacosmos Therapeutics Inc. | 11 | $6,099 |
| Secura Bio, Inc. | 5 | $495 |
| Vertex | 1 | $483 |
| Sanofi-aventis U.S. LLC | 2 | $389 |
| Johnson & Johnson | 4 | $274 |
| Clovis Oncology, Inc. | 1 | $124 |
| Novocure Inc. | 1 | $106 |
| Incyte Corporation | 2 | $91 |
| Geron Corporation | 1 | $90 |
| Morphosys, US Inc. | 3 | $56 |
| AstraZeneca | 2 | $53 |
| AbbVie | 2 | $47 |
| Genentech, Inc. | 1 | $39 |
| Adaptive Biotechnologies Corporation | 1 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Amgen | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $17 |
| Sanofi | 1 | $16 |
How this compares
$943,421 in reported general payments places this provider in the 85th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in New York
- Michael MauroNew York$34.9M
- Adam KittaiNew York$8.2M
- Barry CollerNew York$7.9M
- Ran ReshefNew York$5.4M
- Divaya BhutaniNew York$4.8M
- Richard FurmanNew York$3.1M
- Joseph JurcicNew York$1.7M
- Marissa RybsteinNew York$1.6M
- Allyson OceanNew York$1.5M
- Mark HeaneyNew York$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.